Management of hyperbilirubinaemia in pancreatic cancer patients

Publication date: May 2018
Source:European Journal of Cancer, Volume 94
Author(s): R. Álvarez, A. Carrato, J. Adeva, I. Alés, S. Prados, M. Valladares, T. Macarulla, A. Muñoz, M. Hidalgo
Development of hyperbilirubinaemia is common in patients with advanced pancreatic adenocarcinoma, both at diagnosis as well throughout disease evolution. For this reason, hyperbilirubinaemia determines chemotherapy treatment selection, and therefore it should be considered one of the most relevant conditions. There is very little evidence for the use of chemotherapy in this setting. This article summarises the main causes of hyperbilirubinaemia, how to treat them as well as their differential diagnosis. The current clinical evidence of the available drugs as well as the recommendations of use different combinations in the context of hyperbilirubinaemia are also reviewed.



from Cancer via ola Kala on Inoreader http://ift.tt/2FPnkOK
via IFTTT